DaVita HealthCare Partners Inc. (DVA) Short Interest Update
DaVita HealthCare Partners Inc. (NYSE:DVA) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 5,649,567 shares, a growth of 51.9% from the September 15th total of 3,719,589 shares. Approximately 2.8% of the shares of the company are sold short. Based on an average trading volume of 1,935,475 shares, the short-interest ratio is currently 2.9 days.
In other DaVita HealthCare Partners news, COO Michael David Staffieri sold 20,262 shares of the business’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $73.09, for a total transaction of $1,480,949.58. Following the transaction, the chief operating officer now owns 52,279 shares in the company, valued at approximately $3,821,072.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.10% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the stock. Checchi Capital Advisers LLC boosted its stake in DaVita HealthCare Partners by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 1,556 shares of the company’s stock worth $120,000 after buying an additional 37 shares during the period. Tower Research Capital LLC TRC acquired a new stake in DaVita HealthCare Partners during the second quarter worth $147,000. Mizuho Asset Management Co. Ltd. boosted its stake in DaVita HealthCare Partners by 78.7% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 2,191 shares of the company’s stock worth $169,000 after buying an additional 965 shares during the period. Feltz Wealth PLAN Inc. acquired a new stake in DaVita HealthCare Partners during the second quarter worth $186,000. Finally, Global X Management Co. LLC boosted its stake in DaVita HealthCare Partners by 59.2% in the second quarter. Global X Management Co. LLC now owns 2,422 shares of the company’s stock worth $187,000 after buying an additional 901 shares during the period. 83.54% of the stock is currently owned by institutional investors.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/davita-healthcare-partners-inc-dva-short-interest-update.html
DaVita HealthCare Partners (NYSE:DVA) opened at 62.26 on Tuesday. The stock has a market cap of $12.88 billion, a price-to-earnings ratio of 36.22 and a beta of 0.96. The firm’s 50 day moving average price is $64.41 and its 200-day moving average price is $72.22. DaVita HealthCare Partners has a 52 week low of $61.36 and a 52 week high of $78.94.
DaVita HealthCare Partners (NYSE:DVA) last released its quarterly earnings results on Monday, August 8th. The company reported $1.01 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.98 by $0.03. The company had revenue of $3.72 billion for the quarter, compared to analysts’ expectations of $3.67 billion. DaVita HealthCare Partners had a return on equity of 16.48% and a net margin of 2.51%. The business’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.95 earnings per share. Analysts expect that DaVita HealthCare Partners will post $3.76 EPS for the current year.
Several equities analysts have issued reports on DVA shares. Bank of America Corp. cut DaVita HealthCare Partners from a “buy” rating to a “neutral” rating and set a $70.00 target price on the stock. in a research report on Tuesday, September 6th. Raymond James Financial Inc. upgraded DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating and set a $75.00 target price on the stock in a research report on Tuesday, September 20th. Citigroup Inc. started coverage on DaVita HealthCare Partners in a research report on Tuesday, September 6th. They set a “neutral” rating and a $71.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on DaVita HealthCare Partners from $74.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 9th. Finally, SunTrust Banks Inc. set a $66.00 target price on DaVita HealthCare Partners and gave the stock a “hold” rating in a research report on Thursday, October 13th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $75.50.
DaVita HealthCare Partners Company Profile
DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.